Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines

Pharmacotherapy

Volumn 31, Issue 5, 2011, Pages 441-448

  Kullar, Ravina ^a   Leonard, Steven N ^b   Davis, Susan L ^a,c   Delgado Jr , George ^d   Pogue, Jason M ^e   Wahby, Krista A ^f   Falcione, Bonnie ^g   Rybak, Michael J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d DETROIT RECEIVING HOSPITAL   (United States)

^e SINAI GRACE HOSPITAL   (United States)

^f HARPER UNIVERSITY HOSPITAL   (United States)

^g PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Dosing nomogram; Drug concentration; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CELECOXIB; COLISTIN; CONTRAST MEDIUM; CREATININE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; CLINICAL DECISION MAKING; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NOMOGRAM; PHARMACODYNAMICS; PROSPECTIVE STUDY; TEACHING HOSPITAL; TERTIARY HEALTH CARE; TREATMENT DURATION; VALIDATION PROCESS;

AGED; ANTI-BACTERIAL AGENTS; CREATININE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; VANCOMYCIN;

EID: 79955620196     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.5.441     Document Type: Article

References (36)

1. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006;42(suppl 1):S3-4.
2. Levine DP. Vancomycin: a history. Clin Infect Dis 2006;42(suppl 1):S5-12.
3. Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982;22:391-4. (Pubitemid 13241697)
4. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988;32:848-52.
5. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982;21:575-80. (Pubitemid 12070524)
6. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257-82. (Pubitemid 16050520)
7. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007;44:79-86. (Pubitemid 44968990)
8. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42(suppl 1):S35-9.
9. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12. (Pubitemid 28068148)
10. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984;25:433-7. (Pubitemid 14129598)
11. Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 1999;19:257-66. (Pubitemid 29118168)
12. Lake KD, Peterson CD. Evaluation of a method for initiating vancomycin therapy: experience in 205 patients. Pharmacotherapy 1988;8:284-6. (Pubitemid 19014479)
13. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981;94:343-6. (Pubitemid 11137075)
14. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006;57:699-704.
15. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38:521-8.
16. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007;44:1536-42. (Pubitemid 46871498)
17. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007;51:2582-6. (Pubitemid 47047340)
18. Moise PA, Smyth DS, El-Fawal N, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61:85-90.
19. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402. (Pubitemid 38747480)
20. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillinresistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-20.
21. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200. (Pubitemid 351269157)
22. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
23. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
24. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44.
25. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700-5.
26. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994;16:513-18. (Pubitemid 24296745)
27. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994;18:533-43. (Pubitemid 24106903)
28. Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994;18:544-6.
29. Geraci JE. Vancomycin. Mayo Clin Proc 1977;52:631-4.
30. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23:138-41.
31. Mellor JA, Kingdom J, Cafferkey M, Keane CT. Vancomycin toxicity: a prospective study. J Antimicrob Chemother 1985;15:773-80. (Pubitemid 15064699)
32. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985;16:235-41. (Pubitemid 15002465)
33. Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989;149:1777-81. (Pubitemid 19200833)
34. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6. (Pubitemid 351521995)
35. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14.
36. Rodman DP, McKnight JT, Rogers T, Robbins M. The appropriateness of initial vancomycin dosing. J Fam Pract 1994;38:473-7. (Pubitemid 24145347)